Mark Wefers Bettink

Chapter 7 136 Table 1 . Baseline Patient Characteristics. Variable Controls ( n = 6)* Sepsis ( n = 7)* Age, mean ± SD (y) 64.9 [60 ; 66.2] 63.5 [58.0 ; 65.3] Sex, n (%) Male 5 (83) 3 (43) Female 1 (17) 4 (57) ICU stay (d) 21.1 [18.7 ; 22.8] 7.4 [1.5 ; 24.2] Comorbidities, n (%) 1 (17) 6 (85) Hypertension 1 (17) 2 (29) Coronary artery disease 1 (17) 2 (29) Congestive heart failure 0 0 End stage renal failure 1 (17) 2 (29) Malignancy in history 4 (67) 2 (29) qSOFA criteria, n (%) SBP ≤ 100 mmHg 4 (67) 6 (85) Respiratory rate ≥ 22 min -1 1 (17) 6 (85) GCS < 15 2 (33) 3 (60) Suspected infection 2 (33) 7 (100) Presence of surgery, n (%) 6 (100) 2 (29) 28-day mortality, n (%) 3 (50) 4 (57) Thrombocyte count, (10 9 L -1 ) 168 [144 ; 285] * 261 [51 ; 395] SBP, Systolic blood pressure; qSOFA, quick Sepsis Related Organ Failure Assessment; GCS, Glasgow Coma Scale . Values are given as median [IQR] or n (%) * Laboratory results were not available of one patient ([n=9]) In vivo mitochondrial assessment The ALA-plaster was applied a median of 5.5 [5.0 ; 6.4] hours to the skin preceding the COMET monitor measurement. In 2 patients, quality of signal was not sufficient, so the ALA-plaster was replaced on the skin for 2 hours. The final attempt later that day was successful in only one of these patients, while both had an application time of over 7 hours. The first measurement was conducted 19.8 [15.5 ; 23.2] hours after admission to the ICU for both groups. The median baseline mitoPO 2 for the first and second measurement in the control group were 61.8 [54.0 ; 70.4] and 64.5 [60.8 ± 73.6] mmHg, respectively. The mean baseline mitoPO 2 for the sepsis group was 57.6 [56.4 ; 73.4] mmHg and 69.9 [65.4 ; 74.4] for the first and second measurement respectively. (Figure 2A)